The mainstay of therapy for GvHD is corticosteroids, such as prednisone or methylprednisolone. The reason for this class of medication is that GvHD is characterized by an excessive and abnormal immune response. If these agents do not result in response, second-line treatment options include alternative immunosuppressive agents such as cyclosporine, mycophenolate, tacrolimus, or everolimus. Steroid-refractory GvHD has a poor prognosis, and treatment options are limited if there is no response to steroids. Cell-based therapy has also been studied, but this is not a currently not approved by the Food and Drug Administration (FDA). Cell-based therapies including mesenchymal stem cell (MSC) therapy and T cell depletion.
Graft-versus-host disease medical therapy
Wegeners granulomatosis medical therapy
Mononucleosis medical therapy
Liver transplantation immune therapy
Anthrax medical therapy
Graft-versus-host disease future or investigational therapies
Mixed connective tissue disease medical therapy
Cardiac allograft vasculopathy medical therapy